Tsakiraki, Z.; Spathis, A.; Bouchla, A.; Pouliakis, A.; Vryttia, P.; Panayiotides, I.G.; Pappa, V.; Papageorgiou, S.G.; Foukas, P.G.
Prognostic Role of Adaptive Immune Microenvironment in Patients with High-Risk Myelodysplastic Syndromes Treated with 5-Azacytidine. Cancers 2025, 17, 1104.
https://doi.org/10.3390/cancers17071104
AMA Style
Tsakiraki Z, Spathis A, Bouchla A, Pouliakis A, Vryttia P, Panayiotides IG, Pappa V, Papageorgiou SG, Foukas PG.
Prognostic Role of Adaptive Immune Microenvironment in Patients with High-Risk Myelodysplastic Syndromes Treated with 5-Azacytidine. Cancers. 2025; 17(7):1104.
https://doi.org/10.3390/cancers17071104
Chicago/Turabian Style
Tsakiraki, Zoi, Aris Spathis, Anthi Bouchla, Abraham Pouliakis, Pinelopi Vryttia, Ioannis G. Panayiotides, Vasiliki Pappa, Sotiris G. Papageorgiou, and Periklis G. Foukas.
2025. "Prognostic Role of Adaptive Immune Microenvironment in Patients with High-Risk Myelodysplastic Syndromes Treated with 5-Azacytidine" Cancers 17, no. 7: 1104.
https://doi.org/10.3390/cancers17071104
APA Style
Tsakiraki, Z., Spathis, A., Bouchla, A., Pouliakis, A., Vryttia, P., Panayiotides, I. G., Pappa, V., Papageorgiou, S. G., & Foukas, P. G.
(2025). Prognostic Role of Adaptive Immune Microenvironment in Patients with High-Risk Myelodysplastic Syndromes Treated with 5-Azacytidine. Cancers, 17(7), 1104.
https://doi.org/10.3390/cancers17071104